Welcome to our dedicated page for Astrazeneca Plc SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding AstraZeneca’s labyrinth of R&D updates, patent expirations, and global revenue notes can feel overwhelming. Each disclosure—from breakthrough oncology trial results to collaborative milestone payments—adds pages of technical detail investors must sift through to gauge pipeline risk and earnings power.
Our platform removes that friction. Instantly surface what matters in an AstraZeneca quarterly earnings report 10-Q filing, see every AstraZeneca 8-K material events explained, and monitor AstraZeneca insider trading Form 4 transactions in real time. Stock Titan’s AI reads the fine print, producing plain-English summaries that clarify revenue by therapy area, pending FDA decisions, and cash-flow impacts. Whether you need an AstraZeneca annual report 10-K simplified or want understanding AstraZeneca SEC documents with AI, our expert analysis highlights segment performance, clinical trial spend, and tax considerations without the jargon.
Stay ahead of market-moving disclosures: receive alerts on every AstraZeneca Form 4 insider transactions real-time, explore AstraZeneca earnings report filing analysis for quarter-over-quarter trends, and review the AstraZeneca proxy statement executive compensation to see how bonuses align with pipeline milestones. From income-statement line items to drug-approval catalysts, each filing is linked, searchable, and updated the moment it posts to EDGAR. Make informed decisions faster—no graduate degree in biochemistry required.
AstraZeneca announced positive topline results from the Bax24 Phase III trial showing baxdrostat 2mg once daily met the primary endpoint in patients with treatment-resistant hypertension (rHTN). In a randomized, double-blind study of 218 patients over a 12-week double-blind period, baxdrostat produced a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure versus placebo, with efficacy sustained across the full 24-hour period including the higher-risk morning window. The company reported baxdrostat was generally well tolerated with a safety profile consistent with prior BaxHTN data. AstraZeneca said it will share data with regulators globally and present results at the American Heart Association sessions in
AstraZeneca announced positive Phase III TROPION-Breast02 results for Datroway (datopotamab deruxtecan). The trial enrolled 644 patients and showed a statistically significant and clinically meaningful improvement in both overall survival (OS) and progression-free survival (PFS) versus investigator's choice chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option. Approximately
AstraZeneca reported the total number of voting rights in the company as of 30 September 2025. The company states its issued share capital comprises 1,550,701,945 ordinary shares of US$0.25 and that no shares are held in treasury, giving a total of 1,550,701,945 voting rights. The notice explains this figure can be used by shareholders as the denominator to determine whether they must notify changes in their holdings under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
The disclosure is a routine Transparency Directive update and does not include financial results, transactions, or forward guidance. Contact details for Investor Relations and Media are provided and the report is signed by the Company Secretary, Matthew Bowden, dated 01 October 2025.
AstraZeneca reported positive interim results from the DESTINY-Breast05 Phase III trial showing Enhertu (trastuzumab deruxtecan) produced a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) versus T-DM1 in patients with high-risk HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy. Overall survival was not mature at the interim analysis and will be assessed later. The safety profile was consistent with known data and no new safety concerns were identified. Results will be presented at ESMO 2025 and shared with regulators; the trial enrolled 1,635 patients globally.
AstraZeneca is proposing a Harmonised Listing Structure to permit trading of its ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange by replacing its existing US ADR listing with a direct NYSE listing of ordinary shares. The company will remain headquartered, listed and tax resident in the UK and continue to follow UK governance standards. A Circular with a notice of a general meeting and detailed materials (including updated articles of association and a proxy form) has been published on the company website and filed with the National Storage Mechanism. The announcement includes a cautionary statement that forward-looking expectations involve risks and uncertainties.
AstraZeneca is asking shareholders to approve a Harmonised Listing Structure that would directly list AstraZeneca Shares on the NYSE while keeping listings on the London Stock Exchange and Nasdaq Stockholm. The proposal requires terminating the existing ADR programme, migrating settlement from CREST to DTC, and adopting amended articles to enable issuance of AstraZeneca DIs and, for certain restricted holdings, depositary receipts. The Board unanimously recommends the Resolution. The company highlights growth from $24.7bn revenue in 2015 to $54.1bn in 2024, core operating profit from $6.9bn to $16.9bn and core R&D spend from $5.6bn to $12.2bn; the US accounted for 43% of 2024 revenue and is forecast to be ~50% by 2030. Key dates: General Meeting 3 November 2025 and expected implementation by 2 February 2026.
AstraZeneca PLC reported a director/PDMR shareholding notification: Non-Executive Director Karen Knudsen acquired 9 American Depositary Shares (ADSs) on 9 September 2025 through reinvestment of the first interim dividend for the year ending 31 December 2025, which the company paid on 8 September 2025. Two ADSs equal one ordinary share of $0.25 each. The reported transaction price per ADS was $81.0499. The disclosure was made on 25 September 2025 and follows the EU Market Abuse Regulation reporting requirements.
AstraZeneca and Amgen's Tezspire (tezepelumab) received a positive CHMP recommendation for approval in the EU to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The opinion was based on the Phase III WAYPOINT trial, which showed Tezspire reduced nasal polyp size by a mean of 2.08 points and nasal congestion by 1.04 points versus placebo at Week 52, with p<0.001 for both co-primary endpoints.
WAYPOINT data also reported a 98% near-elimination of the need for surgery and an 89% reduction in systemic corticosteroid use versus placebo. Safety and tolerability were consistent with the known profile. Regulatory reviews are ongoing in multiple other countries.
AstraZeneca reported positive interim Phase III results from the TULIP-SC trial showing subcutaneous Saphnelo (anifrolumab) met the pre-specified primary endpoint of reduced disease activity versus placebo in patients with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). The reduction in disease activity was measured by the BICLA at week 52, which requires improvement across organs without new flares. The interim analysis included the first 220 participants reaching week 52 from a randomised 1:1 trial of 367 participants receiving 120mg subcutaneous anifrolumab once weekly versus placebo on top of standard therapy. Safety was consistent with the known IV profile. Results are under regulatory review and slated for presentation at ACR Convergence 2025.
AstraZeneca reported top-line results from the RESOLUTE Phase III trial of Fasenra (benralizumab) in COPD. The trial randomized 689 participants with moderate to very severe COPD, all on background ICS/LABA/LAMA therapy and with elevated blood eosinophils (≥300 cells/µL). The primary endpoint—annualised rate of moderate or severe exacerbations in patients with ≥3 prior-year exacerbations—showed a numerical improvement with Fasenra but did not reach statistical significance. Safety and tolerability were consistent with Fasenra's known profile. AstraZeneca said it will analyse the full data set and share results with the scientific community. Fasenra is already approved for severe eosinophilic asthma and other eosinophilic conditions in multiple countries.
FAQ
What is the current stock price of Astrazeneca Plc (AZN)?
What is the market cap of Astrazeneca Plc (AZN)?
